{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-074989","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.843066+00:00","generated_at":"2026-05-17T17:57:08.363706+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Replimune reports Q1 FY2026 net loss $86.7M; FDA issues CRL for RP1 BLA","bullets":["Net loss of $86.7M for quarter ended June 30, 2025, vs $53.8M a year ago.","Cash, cash equivalents and short-term investments $403.3M; funding expected into Q4 2026.","FDA issued Complete Response Letter for RP1 BLA in advanced melanoma on July 22, 2025.","R&D expenses $57.8M (up from $43.0M); SG&A $32.6M (up from $14.4M), driven by commercial prep.","Ongoing Phase 3 IGNYTE-3 trial for RP1+nivolumab; Phase 2/3 REVEAL trial for RP2 in uveal melanoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-074989","json":"https://secwatch.observer/filing/0001104659-25-074989.json","markdown":"https://secwatch.observer/filing/0001104659-25-074989.md","text":"https://secwatch.observer/filing/0001104659-25-074989.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925074989/0001104659-25-074989-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925074989/tm2522849d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:57:08.363706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}